Research at Bayer

Innovation plays an important role in overcoming global challenges and is a key driver of future growth at Bayer.

In 2009 Bayer spent €2,746 million on research and development (r&d), which was equivalent to 8.8 percent of sales. Special importance is placed on developing new products that strengthen the core businesses. Mindful of its corporate growth objectives, Bayer works to continuously rejuvenate and expand its product portfolio and optimize its production processes. Its r&d is closely aligned to market requirements and therefore subject to a continuous process of adjustment. It is supplemented by an international network of collaborations with leading universities, publicsector research institutes and partner companies. Through this pooling of expertise, Bayer aims to rapidly translate new ideas into successful products. These activities are also supported by systematic employee development in the company’s r&d units.

Triple-i is a global initiative to tap into our creative potential.

More than 7,000 suggestions have already been submitted in response to the innovation initiative launched by Bayer AG in 2007, entitled “Triple-i: Inspiration, Ideas, Innovation.” Many of these proposals are currently undergoing further evaluation by our subgroups. The initiative is designed to motivate employees throughout the Group to submit ideas for new products and thus help to strengthen Bayer’s innovation capability.